Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-09-02 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于持股5%以上股东股份被司法冻结的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the judicial freezing of shares held by a shareholder owning more than 5% of the company's stock. It details the shareholder's name, the number of shares frozen, the legal authority involved, and the impact on the company. There is no financial data, no report attached or referenced as being published, and no mention of management changes or other report types. This fits the definition of a Major Shareholding Notification (MRQ), specifically about a change in significant share ownership status due to judicial freezing.
2021-09-02 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2021年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021 年半年度持续督导跟踪报告" (2021 Half-Year Continuous Supervision Follow-up Report) issued by the sponsor (广发证券股份有限公司) for the listed company 上海美迪西生物医药股份有限公司. It references regulatory frameworks related to continuous supervision after IPO on the Shanghai Stock Exchange Sci-Tech Innovation Board (科创板). The content includes detailed descriptions of the sponsor's ongoing supervision activities, risk factors, financial data for the first half of 2021, compliance with fundraising usage, and shareholding information of directors and senior management. The document contains substantive financial data and analysis for the half-year period, including income, profit, cash flow, and R&D expenses, as well as management discussion of risks and operational status. This matches the characteristics of an Interim / Quarterly Report (IR) rather than a full Annual Report (10-K) or a simple announcement. It is not a certification, announcement, or proxy material. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-30 Chinese
美迪西：监事会关于公司2021年限制性股票激励计划激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the Supervisory Board regarding the verification and disclosure of the list of incentive recipients under the company's 2021 restricted stock incentive plan. It includes legal references, details about the public disclosure period, and the Supervisory Board's verification opinion confirming the eligibility and compliance of the incentive recipients. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement related to the stock incentive plan and the verification of the incentive recipients. This fits best under Regulatory Filings (RNS), as it is a regulatory disclosure that does not fit other specific categories like capital changes or remuneration reports.
2021-08-27 Chinese
美迪西：2021年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled '2021 年第一次临时股东大会会议资料' which translates to '2021 First Extraordinary General Meeting (EGM) Meeting Materials' of Shanghai Medicilon Inc. It contains detailed meeting instructions, agenda, and proposals to be discussed and voted on during the shareholders' meeting. The content includes meeting procedures, voting methods, and specific proposals related to stock incentive plans and authorizations for the board to handle related matters. There is no financial data or results reported, nor is it a transcript or announcement of voting results. The document is clearly the meeting materials provided to shareholders for the EGM, which fits the definition of AGM Information (AGM-R), as it is the presentation and materials shared during a general meeting (in this case, an extraordinary general meeting). The document length is over 6,800 characters, indicating it is the full meeting materials, not just an announcement of a report. Therefore, the correct classification is AGM Information (AGM-R).
2021-08-25 Chinese
美迪西：2021年限制性股票激励计划激励对象名单
Board/Management Information Classification · 95% confidence The document is titled as a list of incentive recipients under a 2021 restricted stock incentive plan by Shanghai Medicilon Inc. It details the allocation of restricted stock to various employees and other personnel deemed necessary by the board. The content focuses on stock incentive plan details and the list of recipients, which is a form of management or board information related to compensation and stock incentives. It does not contain financial statements, audit information, or voting results. It is not a report or announcement of a report but a detailed disclosure of stock incentive allocations. This type of document aligns best with Board/Management Information (MANG), as it relates to management decisions and board-approved incentive plans.
2021-08-17 Chinese
美迪西：2021年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a 2021 restricted stock incentive plan by Shanghai Medicilon Biopharmaceutical Co., Ltd. It details the purpose, principles, scope, assessment institutions, performance indicators, procedures, and management of the stock incentive plan. It is a governance-related document focusing on the company's internal rules and mechanisms for stock incentives, rather than a financial report, earnings release, or announcement. It does not contain financial statements or earnings data, nor is it a regulatory announcement or voting result. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2021-08-17 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.